<DOC>
	<DOCNO>NCT01541397</DOCNO>
	<brief_summary>Prospective study compare bone mineral density adult HPA KUVAN™ therapy therapy . The investigator hypothesize one year KUVAN™ therapy , improvement bone mineral density .</brief_summary>
	<brief_title>Bone Mineral Density Adults With Hyperphenylalaninemia Kuvan Therapy</brief_title>
	<detailed_description>Hyperphenylalaninemia ( HPA ) rare metabolic disorder cause deficiency enzyme phenylalanine hydroxylase ( PAH ) ( NIH , October 16-18 , 2000 ) . Elevated plasma level phenylalanine ( phe ) cause mental retardation , microcephaly , delay speech , seizure , eczema , behavior abnormality . Adequate control plasma level phe phe-restricted diet prevent developmental behavioral problem . The foundation diet phe-free metabolic medical product/formula make free amino acid . Based longitudinal study , report benefit attained individual maintain phe-restricted diet throughout life . On December 13 , 2007 , KUVAN™ ( sapropterin dihydrochloride ) approve FDA indication reduce blood phe level patient HPA due BH4 responsive PKU , conjunction phe restrict diet ( BioMarin Pharmaceutical Inc. , Investigator 's Brochure March 25 , 2008 ) . Studies perform determine definition response KUVAN™ . In phase 2 clinical trial 2007 , Burton , et . al . define Kuvan™ responder 30 % great improvement blood phenylalanine level compare baseline 8 day drug therapy . Kuvan™ show improve phenylalanine tolerance individual HPA . This drug enable individual consume protein natural source . However , research study assess effect KUVAN™ along liberalization diet bone mineral density . The investigator propose prospective study compare bone mineral density adult HPA KUVAN™ therapy therapy . The investigator hypothesize one year KUVAN™ therapy , improvement bone mineral density .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<criteria>Diagnosis hyperphenylalaninemia birth Age 18 50 year Participated study HSCMS1100262 Perimenopausal menopausal woman exclude time increase bone loss relate hormonal mediated factor . Patients take bisphosphonates alters bone density . Therefore , bone mineral density would reflect biphosphonate intervention rather true status . Pregnant woman due hazard radiation exposure DXA scan . In addition woman pregnant breastfed within one year study enrollment exclude period rapid bone loss would reflect entity study would serve confound data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hyperphenylalaninemia</keyword>
	<keyword>Phenylketonuria</keyword>
	<keyword>Adults</keyword>
	<keyword>Bone Mineral Density</keyword>
</DOC>